July 26 (Reuters) - Insulet ( PODD ) reported

preliminary second-quarter revenue above Wall Street estimates

on Friday, as it benefited from strong demand for its insulin

delivery devices.

The Massachusetts-based company manufactures and sells

insulin delivery devices, under brand Omnipod, which eliminate

the need for multiple daily injections using syringes or insulin

pens for people with insulin-dependent diabetes.

The company said it expects to raise its full-year Omnipod

revenue growth forecast to a range of 18% to 21% compared to its

previous range of 15% to 19%, when it releases its quarterly

results on Aug. 8.

Late on Thursday, larger peer Dexcom ( DXCM ) slashed its

annual revenue forecast due to an internal restructuring of its

sales force and less-than-expected new patients, causing its

shares to plunge about 35% in premarket trading on Friday.

Insulet ( PODD ) reported preliminary second-quarter revenue of $488

million, compared with analysts' average estimate of $460.3

million, according to LSEG data.

Shares of the medical device maker rose about 6% before the

bell.

(Reporting by Christy Santhosh in Bengaluru; Editing by

Shinjini Ganguli)